These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37960806)

  • 61. The prognostic value of the urokinase-plasminogen activator system (uPA) in bladder cancer patients treated with radical cystectomy (RC).
    Janisch F; D'Andrea D; Iwata T; Kimura S; Abufaraj M; Enikeev D; Glybochko PV; Karakiewicz PI; Nyirady P; Fajkovic H; Haitel A; Seebacher V; Rink M; Shariat SF
    Urol Oncol; 2020 May; 38(5):423-432. PubMed ID: 32209281
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The significance of urokinase- type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer.
    Chambers SK; Gertz RE; Ivins CM; Kacinski BM
    Cancer; 1995 Apr; 75(7):1627-33. PubMed ID: 8826920
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Correlation of Serum Levels of Urokinase Activation Plasminogen (uPA) and Its Inhibitor (PAI-1) with Hormonal and HER-2 Status in the Early Invasive Breast Cancer.
    Pusina S
    Med Arch; 2018 Nov; 72(5):335-340. PubMed ID: 30524164
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Nipple aspirate fluid expression of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor predicts breast cancer diagnosis and advanced disease.
    Qin W; Zhu W; Wagner-Mann C; Sauter ER
    Ann Surg Oncol; 2003 Oct; 10(8):948-53. PubMed ID: 14527916
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Plasminogen Activation System in Rectal Adenocarcinoma.
    Razik E; Kobierzycki C; Grzegrzolka J; Podhorska-Okolow M; Drag-Zalesinska M; Zabel M; Dziegiel P
    Anticancer Res; 2015 Nov; 35(11):6009-15. PubMed ID: 26504024
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
    Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
    Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Insulin-like growth factor-II mRNA binding protein-3 and podoplanin expression are associated with bone invasion and prognosis in oral squamous cell carcinoma.
    Hwang YS; Ahn SY; Moon S; Zheng Z; Cha IH; Kim J; Zhang X
    Arch Oral Biol; 2016 Sep; 69():25-32. PubMed ID: 27232357
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma.
    Speleman L; Kerrebijn JD; Look MP; Meeuwis CA; Foekens JA; Berns EM
    Head Neck; 2007 Apr; 29(4):341-50. PubMed ID: 17163465
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
    Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
    Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
    Borstnar S; Vrhovec I; Svetic B; Cufer T
    Clin Breast Cancer; 2002 Jun; 3(2):138-46. PubMed ID: 12123538
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
    Duffy MJ; Duggan C
    Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Urokinase-Type Plasminogen Activator Receptor (uPAR) Expression and [
    Lawaetz M; Binderup T; Christensen A; Juhl K; Lelkaitis G; Lykke E; Knudsen L; von Buchwald C; Kjaer A
    Mol Imaging Biol; 2023 Dec; 25(6):1034-1044. PubMed ID: 37749438
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
    Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
    Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Impact of uPA system gene polymorphisms on the susceptibility of environmental factors to carcinogenesis and the development of clinicopathology of oral cancer.
    Weng CJ; Lin CW; Chung TT; Tsai CM; Chen MK; Yang SF
    Ann Surg Oncol; 2011 Mar; 18(3):805-12. PubMed ID: 21125336
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer.
    Christensen A; Kiss K; Lelkaitis G; Juhl K; Persson M; Charabi BW; Mortensen J; Forman JL; Sørensen AL; Jensen DH; Kjaer A; von Buchwald C
    BMC Cancer; 2017 Aug; 17(1):572. PubMed ID: 28841839
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus.
    Nekarda H; Schlegel P; Schmitt M; Stark M; Mueller JD; Fink U; Siewert JR
    Clin Cancer Res; 1998 Jul; 4(7):1755-63. PubMed ID: 9676852
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
    Grøndahl-Hansen J; Christensen IJ; Briand P; Pappot H; Mouridsen HT; Blichert-Toft M; Danø K; Brünner N
    Clin Cancer Res; 1997 Feb; 3(2):233-9. PubMed ID: 9815678
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.
    Harbeck N; Kates RE; Schmitt M
    J Clin Oncol; 2002 Feb; 20(4):1000-7. PubMed ID: 11844823
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors.
    Jahkola T; Toivonen T; von Smitten K; Virtanen I; Wasenius VM; Blomqvist C
    Br J Cancer; 1999 Apr; 80(1-2):167-74. PubMed ID: 10389993
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The urokinase plasminogen activator system: role in malignancy.
    Duffy MJ
    Curr Pharm Des; 2004; 10(1):39-49. PubMed ID: 14754404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.